Therefore, identification of metalloprotease-dependent spike protein-induced ACE2 shedding as a contributor to SARS-CoV-2 cell–cell fusion supports the inhibition of metalloproteases as a treatment for patients with COVID-19. This evidence concerns the gene ACE2 and COVID-19.